Top Stories
The neuropsychiatry biotech builds on last year's $140 million launch as Phase II studies of its lead depression drug DT-101 continue.
Avere's deal with Hansoh Pharmaceutical, potentially worth over $2 billion, is backed by a $320-million private placement.
After partner GSK successfully gained FDA approval of the antibiotic Utebzi (tebipenem pivoxil) in June, Spero is pivoting to immunology and inflammation via a licensing agreement with Innovent Biologics.
The oral EGFR inhibitor is approved in China and the US for previously-treated EGFR exon 20 insertion-positive non–small-cell lung cancer, and is pursuing a first-line indication.
The PPAR agonist met its primary endpoint in the Phase IIIb ELSPIRE trial involving patients with primary biliary cholangitis (PBC) and alkaline phosphatase levels 1 to 1.67 times the upper limit of normal.
Conference News
Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with place...
• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.TORONTO, July 14, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc...
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026Preclinical data for sutacimig in Factor VII d...
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –– Updated data expected to support darlif...
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)New analys...
